BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Events//NONSGML v1.0//EN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTART;TZID="Pacific Time (US & Canada)":20230328T123000
DTEND;TZID="Pacific Time (US & Canada)":20230328T132000
SUMMARY:Organic Chemistry Seminar – Aaron Hendricksen, Chemistry Graduate Student
LOCATION:Fulmer Hall
DESCRIPTION:Speaker: Aaron Hendricksen, chemistry graduate student\n\nTitle: Thermophobic Trehalose Glycopolymers as Smart C-Type Lectin Receptor Vaccine Adjuvants\n\nAbstract: Adjuvant additives significantly increase vaccine efficacy. However, adjuvants also cause inflammatory side-effects, such as pyrexia, which currently limits their use. To address this, we created a thermophobic vaccine adjuvant engineered to attenuate potency at temperatures correlating to pyrexia. Thermophobic adjuvants were synthesized by combining a rationally designed trehalose glycolipid CLR agonist with thermoresponsive poly-N-isoporpylacrylamide (NIPAM) via Reversible Addition-Fragmentation Chain-Transfer polymerization. The resulting thermophobic adjuvants exhibited LCSTs near 37 °C, and self-assembled into nanoparticles with temperature-dependent sizes (90-270nm). Thermophobic adjuvants activated HEK-mMINCLE and other innate immune cell lines as well as primary mouse Bone Marrow-Derived Dendritic Cells and Macrophages. Inflammatory cytokine production was attenuated under conditions mimicking pyrexia (above the LCST) relative to homeostasis (37 °C) or below the LCST. This thermophobic behavior correlated with decreased adjuvant Rg observed by DLS, as well as glycolipid-NIPAM shielding interactions observed by NOESY-NMR. In-vivo, thermophobic adjuvants enhanced efficacy of a whole inactivated Influenza A/California/04/2009 virus vaccine, by increasing neutralizing antibody titers and CD4+ /44+ /62L+ lung and lymph node central memory T cells, as well as providing better protection from morbidity after viral challenge relative to unadjuvanted control vaccine. Together, these results demonstrate the first adjuvants with potency regulated by temperature. We envision that with further investigation, this approach could enhance vaccine efficacy while maintaining safety.
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:REMINDER
TRIGGER;RELATED=START:-PT00H15M00S
END:VALARM
END:VEVENT
END:VCALENDAR